This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Vaquerano, J. Articles by Kane, J. M. Search for Related Content PubMed PubMed Citation Articles by Vaquerano, J. Articles by Kane, J. M., III

American Joint Committee on Cancer Clinical Stage as a Selection Criterion for Sentinel Lymph Node Biopsy in Thin Melanoma

¹ Department of Surgical Oncology, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, New York 14263
² Department of Pathology, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, New York 14263

Correspondence: Address correspondence and reprint requests to: John M. Kane III, MD; E-mail: john.kane{at}roswellpark.org.

Background: A significant proportion of newly diagnosed melanomas are thin lesions ( 1.00 mm). Because tumor thickness correlates with the risk for nodal metastases, sentinel lymph node (SLN) biopsy in this subset is controversial. Incorporating other prognostic factors (Clark level and ulceration), we evaluated the 6th edition American Joint Committee on Cancer (AJCC) clinical stage as a simple and widely applicable guideline for offering SLN biopsy for thin melanoma.

Methods: This study was a review of a prospective melanoma SLN database from 1993 to 2003 with emphasis on SLN positivity rates based on the 6th edition AJCC primary tumor thickness intervals and clinical stage.

Results: Three hundred five patients underwent SLN biopsy, with an overall positivity rate of 17.7%. By the 6th edition AJCC, lesions 1.00 mm had an SLN positivity rate of 6.6%. By 6th edition clinical stage, SLN positivity rates were 4.9% for stage IA and 10.4% for stage IB. By using stage IA as the criterion for not offering SLN biopsy, this procedure would have been avoided in 46% (39 of 85) of 1.00-mm melanoma patients with a negative SLN.

Conclusions: Sixth edition AJCC clinical stage IB as a selection criterion for performing SLN biopsy in thin melanoma identifies most patients with a positive SLN while also avoiding a negative SLN biopsy in many patients. Until additional widely accepted and validated selection criteria are available, SLN biopsy for clinical stage IB, but not stage IA, thin melanomas is a reasonable approach.

Key Words: Thin melanoma • Sentinel lymph node • Clinical stage • Prognostic factors

This article has been cited by other articles:

				C. Mathelin, S. Salvador, D. Huss, and J.-L. Guyonnet Precise Localization of Sentinel Lymph Nodes and Estimation of Their Depth Using a Prototype Intraoperative Mini {gamma}-Camera in Patients with Breast Cancer J. Nucl. Med., April 1, 2007; 48(4): 623 - 629. [Abstract] [Full Text] [PDF]